Our vision is to overcome obesity.

Key Takeaways from the Economist Enterprise Obesity & Metabolic Health Summit 2026

New real-world data from over 40,000 patients show that digital obesity care produces significant and sustained weight loss even with low medication doses.

UK employers are increasingly considering weight-loss support as part of employee benefits, as new Yazen patient data links GLP-1 treatment to reduced sick days and improved workplace performance.

In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.

Yazen presents an oral scientific abstract at the Nordic Obesity Meeting (NOM26), highlighting high-volume patient–caregiver interactions in a fully digital obesity care model.

The WHO released its first global guideline for GLP-1 obesity treatment, recognizing obesity as a chronic disease. Long-term care combined with therapy is key.

Yazen wins “Weight Loss Treatment of the Year 2025 award” for its innovative, evidence-based care helping over 47,000 patients achieve sustainable weight loss.

Yazen named the fastest-growing startup in the Nordics and Benelux in the Sifted 100 Leaderboard

Yazen partners with Withings to go beyond BMI for better health insights.

Yazen expands in Scandinavia through the acquisition of Danish company Medstart, which is established in Denmark and Norway. Together, they enhance care for people with obesity.

Yazen has secured €19.5 million in Series A funding to expand its GLP-1-based obesity treatment across Europe. The company combines medication with lifestyle support for sustainable weight loss results.

Yazen Health has successfully closed an oversubscribed €19.5 million series A funding round to fuel its international expansion. This investment enables Yazen to enhance its pioneering obesity treatment model, combining modern weight loss medication with comprehensive lifestyle support.

Lasker~DeBakey Award 2024 for groundbreaking GLP-1 obesity research

GLP-1 weight loss drugs like Wegovy are attracting startups and investors, aiming to tap into the projected $150bn market despite supply and reimbursement challenges

Join Health Tech World's webinar with experts discussing sustainable weight loss through medication, lifestyle changes, and digital health tools. Watch now!

Study shows GLP-1 agonists reduce dementia risk in elderly with type 2 diabetes. Findings from KI highlight potential benefits for diabetes treatment

Medical Product Alert: Fake Ozempic (semaglutide) Detected in Americas and Europe

Wigan named UK's 'Fattest Town' - Yazen Health tackles obesity safely

The obesity epidemic is one of the greatest health challenges of our time. Globally, it is estimated that 1.9 billion people will suffer from morbid obesity by 2035, which represents one in four adults. Among children, obesity is expected to increase by 100 percent between 2020 and 2035. The cost to society is projected to be 4 trillion dollars.

Martin Carlsson participates in "Where next for digital health? A roundtable debate hosted by Health Tech World